{"id":"xaliproden-sr57746a","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1512580","moleculeType":"Small molecule","molecularWeight":"381.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It is believed to exert its effects by reducing excitotoxicity and promoting neuronal survival. This is thought to be beneficial in the treatment of neurodegenerative diseases such as Alzheimer's disease. However, the exact mechanism of action is not fully understood.","oneSentence":"Xaliproden acts as a neuroprotective agent by modulating the activity of the NMDA receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:04.246Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00603577","phase":"PHASE3","title":"Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-01","conditions":"Colorectal Neoplasms","enrollment":102},{"nctId":"NCT00305188","phase":"PHASE3","title":"Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-12","conditions":"Metastases, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":879},{"nctId":"NCT00103649","phase":"PHASE3","title":"18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Alzheimer Disease","enrollment":1306},{"nctId":"NCT00104013","phase":"PHASE3","title":"Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Alzheimer Disease","enrollment":1455},{"nctId":"NCT00272051","phase":"PHASE3","title":"XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-07","conditions":"Metastases, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":620}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Xaliproden (SR57746A)","genericName":"Xaliproden (SR57746A)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xaliproden (SR57746A) is a small molecule serotonin 1a (5-HT1a) receptor agonist. It has been studied in clinical trials for conditions including Alzheimer Disease, Metastases, Colorectal Neoplasms, and Colorectal Carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}